Skip to main content

Zanubrutinib Side Effects

Medically reviewed by Philip Thornton, DipPharm. Last updated on Sep 19, 2022.

For the Consumer

Applies to zanubrutinib: oral capsules

Side effects include:

Decreased neutrophil count, decreased platelet count, upper respiratory tract infection, decreased WBC count, decreased hemoglobin concentration, rash, bruising, diarrhea, cough.

For Healthcare Professionals

Applies to zanubrutinib: oral capsule

Hematologic

Very common (10% or more): All grades neutropenia (up to 56%), all grades thrombocytopenia (up to 45%) , hemorrhage (up to 32%), all grades anemia (up to 28%) , all grades leukopenia (25%)

Common (1% to 10%): Grade 3 or 4 anemia, Grade 3 or 4 leukopenia, Grade 3 or 4 thrombocytopenia[Ref]

Immunologic

Very common (10% or more): Grade 3 or higher infection (23%)[Ref]

Musculoskeletal

Very common (10% or more): Musculoskeletal pain (e.g., musculoskeletal pain, musculoskeletal discomfort, myalgia, back pain, arthralgia, arthritis) (up to 45%), muscle spasms (10%)[Ref]

Metabolic

Very common (10% or more): Glucose increased (45%), blood uric acid increased (up to 29%), hypokalemia (14%), calcium decreased (27%), hyperkalemia (24%), hypophosphatemia (20%)

Genitourinary

Very common (10% or more): Urinary tract infection (up to 15%)[Ref]

Hepatic

Very common (10% or more): ALT increased (28%), bilirubin increased (up to 24%)

Common (1% to 10%): Hepatitis B reactivation[Ref]

Oncologic

Very common (10% or more): Second primary malignancies (13%)[Ref]

Respiratory

Very common (10% or more): Upper respiratory tract infection (up to 44%), pneumonia (up to 22%), cough (up to 21%)[Ref]

Cardiovascular

Very common (10% or more): Hypertension (12%)

Common (1% to 10%): Atrial fibrillation, atrial flutter[Ref]

Dermatologic

Very common (10% or more): Rash (up to 30%), bruising (up to 20%), pruritus (11%)[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (up to 23%), constipation (up to 16%), nausea (18%)

Uncommon (0.1% to 1%): Gastrointestinal hemorrhage[Ref]

General

The most common adverse events were neutropenia, thrombocytopenia, upper respiratory tract infection, hemorrhage, rash, anemia and musculoskeletal pain.

Renal

Very common (10% or more): Creatinine increased (31%)

Other

Very common (10% or more): Fatigue (up to 15%), peripheral edema (12%), pyrexia (16%)

Common (1% to 10%): Asthenia

Nervous system

Very common (10% or more): Dizziness (11%)

Frequently asked questions

References

1. "Product Information. Brukinsa (zanubrutinib)." BeiGene USA, Inc (2019):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.